View full meeting coverage »

Eyetube Meeting Coverage:

Meeting Coverage Cancun 2017

You are watching a 25-second preview
Log in to keep watching

You are watching a 25-second preview Log in to keep watching

You are watching a 25-second preview
Log in to keep watching

Replay

Cancel

Your 25-second video preview has ended.

to continue watching, please Log In or Register:

Log in / Register

New Drug Class Shows Potential for Glaucoma

Jason Bacharach, MD

Channels: Glaucoma | Posted 2/5/2017

Jason Bacharach, MD, discussed his excitement regarding results from studies of netarsudil (Aerie), a potential first in a new class of glaucoma medications in 2 decades. The agent was found to be noninferior to timolol in the Rocket 1 and Rocket 2 studies. He also spoke about a fixed-dose agent from the company, PG324, a combination of netarsudil and latanoprost. This would potentially be the first fixed-dose combination drug that contains a prostaglandin available in the United States.

13 / 15 Series: Meeting Coverage Cancun 2017

Jason Bacharach, MD Channels: Glaucoma | Posted 2/5/2017

Jason Bacharach, MD, discussed his excitement regarding results from studies of netarsudil (Aerie), a potential first in a new class of glaucoma medications in 2 decades. The agent was found to be noninferior to timolol in the Rocket 1 and Rocket 2 studies. He also spoke about a fixed-dose agent from the company, PG324, a combination of netarsudil and latanoprost. This would potentially be the first fixed-dose combination drug that contains a prostaglandin available in the United States.

Keywords

Comments view all

. United States - today

Post Comment
post as anonymous

More Videos in this Series

1

Don't Wrestle the Pupil!

Johnny Gayton, MD

MIGS Gets Complicated

Ike Ahmed, MD

Femtosecond Laser in High-Risk Patients

Mark Tomalla, MD

Corneal Inlays: Getting it Right

Jeff Machat, MD, FRCSC, DABO

Nonimplant Surgery: What Are the Options…

Karl Stonecipher, MD

LASIK Flap Complications

Priyanka Sood, MD

Delivering No-Glasses Vision

Jack T. Holladay MD, MSEE, FACS

EDOF Lens Behaves Like a Progressive IOL

Maria Scott, MD

Good Products, Bad Choices

Doug Katsev, MD

Demodex Blepharitis

Anita Nevyas-Wallace, MD

The Iris Protection Plan

Denise Visco, MD

Dry Eye Review

Shazia Ahmed, MD

New Drug Class Shows Potential for Glauc…

Jason Bacharach, MD

Compounded Medications for Cataract, Ref…

Damien Goldberg, MD

Working Smarter, Not Harder!

Eric D. Donnenfeld, MD

View full meeting coverage (15 videos)

1

Compounded Medications for Cataract, Refractive, Glaucoma, and DED Patients

Damien Goldberg, MD

Working Smarter, Not Harder!

Eric D. Donnenfeld, MD